Kameel D. Farag - 01 Nov 2025 Form 4 Insider Report for Akari Therapeutics Plc (AKTX)

Role
Interim CFO
Signature
/s/ Abizer Gaslightwala, Attorney-in-Fact
Issuer symbol
AKTX
Transactions as of
01 Nov 2025
Transactions value $
$43,964
Form type
4
Filing time
04 Nov 2025, 17:00:02 UTC
Previous filing
24 Oct 2025
Next filing
18 Dec 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Farag Kameel D. Interim CFO C/O AKARI THERAPEUTICS PLC, 401 EAST JACKSON STREET, SUITE 3300, TAMPA /s/ Abizer Gaslightwala, Attorney-in-Fact 04 Nov 2025 0002093620

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AKTX American Depositary Shares representing Ordinary Shares Award $24K +32K $0.75 32K 01 Nov 2025 Direct F1, F2
transaction AKTX American Depositary Shares representing Ordinary Shares Award $20K +26.6K $0.75 26.6K 01 Nov 2025 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer
F2 These ADSs represent restricted stock units ("RSUs"), with each such RSU representing the right to receive 2,000 Ordinary Shares par value $0.0001. The RSUs shall vest on January 1, 2026.
F3 These ADSs represent restricted stock units ("RSUs"), with each such RSU representing the right to receive 2,000 Ordinary Shares par value $0.0001. The RSUs shall vest on February 15, 2026.